Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) has issued an update.
Charmacy Pharmaceutical Co., Ltd. has issued a clarification regarding its 2025 annual results announcement, correcting a clerical error in the note on return on net assets and earnings per share within the financial statements. The revised figures specify weighted average return on net assets and basic and diluted earnings per share for net profit attributable to ordinary shareholders, both including and excluding non-recurring items.
The company emphasized that the correction is limited to this specific note and does not affect any other financial information disclosed in the original 2025 results announcement. All other data in the annual results remain unchanged, indicating that the adjustment is technical in nature and should not alter investors’ overall assessment of the group’s reported performance.
The most recent analyst rating on (HK:2289) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Charmacy Pharmaceutical Co., Ltd. Class H stock, see the HK:2289 Stock Forecast page.
More about Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. is a joint stock limited liability company incorporated in the People’s Republic of China and listed in Hong Kong. The company operates in the pharmaceutical sector, focusing on drug-related businesses and serving the mainland China healthcare market through its group structure and listed H-share platform.
Average Trading Volume: 10,600
Technical Sentiment Signal: Sell
Current Market Cap: HK$628.6M
For an in-depth examination of 2289 stock, go to TipRanks’ Overview page.